Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,196.00
(
-1.18%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.50
(
-1.20%
)
Bitcoin
81,163.83
(
0.84%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

EndoTarget

Send PM Follow Ignore
Followers 21
Posts 1473
Boards Moderated 0
Alias Born 05/07/2015

EndoTarget

Re: PGG76109 post# 336409

Saturday, 01/30/2021 9:19:14 PM

Saturday, January 30, 2021 9:19:14 PM

Post# of 347009
https://clinicaltrials.gov/ct2/show/NCT04099641

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

This study evaluates the combination of bavituximab and pembrolizumab in the treatment of gastric and gastroesphogeal cancer. All patients will receive both bavituximab, a drug that is not yet approved by the FDA, and pembrolizumab known as Keytruda.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote